{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Staphylococcus+Aureus+Bacteremia&page=2",
    "query": {
      "condition": "Staphylococcus Aureus Bacteremia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Staphylococcus+Aureus+Bacteremia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T11:04:29.297Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04775953",
      "title": "DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcal Bacteraemia"
      ],
      "interventions": [
        {
          "name": "Cefazolin",
          "type": "DRUG"
        },
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Daptomycin",
          "type": "DRUG"
        },
        {
          "name": "Nafcillin",
          "type": "DRUG"
        },
        {
          "name": "Oxacillin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 200,
      "start_date": "2021-04-22",
      "completion_date": "2023-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04775953"
    },
    {
      "nct_id": "NCT01198262",
      "title": "Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Staphylococcus Aureus",
        "Staphylococcal Skin Infections",
        "Bacteremia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Michael E. DeBakey VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2008-04",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2010-09-10",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01198262"
    },
    {
      "nct_id": "NCT00062647",
      "title": "Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gram-Positive Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin, nafcillin, oxacillin, or cloxacillin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2003-08",
      "completion_date": "2006-08",
      "has_results": true,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 1,
      "location_summary": "Marietta, Georgia",
      "locations": [
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062647"
    },
    {
      "nct_id": "NCT05329168",
      "title": "ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bacteremia Due to Staphylococcus Aureus",
        "Left Sided Infective Endocarditis (Disorder)",
        "Right Sided Infective Endocarditis (Disorder)",
        "Endocarditis Infective"
      ],
      "interventions": [
        {
          "name": "Tonabacase (LSVT-1701)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lysovant",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-05-01",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 1,
      "location_summary": "Butte, Montana",
      "locations": [
        {
          "city": "Butte",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05329168"
    },
    {
      "nct_id": "NCT05975671",
      "title": "Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sepsis",
        "Sepsis Mrsa",
        "Sepsis Bacteremia",
        "Antimicrobial - Induced Nephropathy",
        "Sepsis, Severe",
        "Septic Shock",
        "Septic Syndrome"
      ],
      "interventions": [
        {
          "name": "Multifaceted de-implementation strategy to reduce vancomycin overuse",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 52500,
      "start_date": "2023-08-21",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05975671"
    },
    {
      "nct_id": "NCT04160468",
      "title": "Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Staphylococcus Aureus Bacteremia",
        "Staphylococcus Aureus Endocarditis"
      ],
      "interventions": [
        {
          "name": "Exebacase",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ContraFect",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 259,
      "start_date": "2019-12-20",
      "completion_date": "2022-09-09",
      "has_results": true,
      "last_update_posted_date": "2023-11-02",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Orange, California • Sacramento, California + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04160468"
    },
    {
      "nct_id": "NCT00695903",
      "title": "Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endocarditis, Bacterial",
        "Infective Endocarditis"
      ],
      "interventions": [
        {
          "name": "daptomycin",
          "type": "DRUG"
        },
        {
          "name": "vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2008-09-17",
      "completion_date": "2010-10-01",
      "has_results": true,
      "last_update_posted_date": "2018-12-24",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 2,
      "location_summary": "Greenville, North Carolina • Cleveland, Ohio",
      "locations": [
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00695903"
    },
    {
      "nct_id": "NCT01919762",
      "title": "Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bacteremia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "T2 Biosystems",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 156,
      "start_date": "2013-08",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2015-09-28",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 1,
      "location_summary": "Camden, New Jersey",
      "locations": [
        {
          "city": "Camden",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01919762"
    },
    {
      "nct_id": "NCT02439359",
      "title": "A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)"
      ],
      "interventions": [
        {
          "name": "CF-301",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ContraFect",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-05",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Omaha, Nebraska",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02439359"
    },
    {
      "nct_id": "NCT02660346",
      "title": "IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bacteremia"
      ],
      "interventions": [
        {
          "name": "Daptomycin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Ceftaroline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sharp HealthCare",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-11",
      "completion_date": "2018-01-30",
      "has_results": false,
      "last_update_posted_date": "2018-02-01",
      "last_synced_at": "2026-06-11T11:04:29.297Z",
      "location_count": 2,
      "location_summary": "La Mesa, California • San Diego, California",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02660346"
    }
  ]
}